Literature DB >> 8980918

Pharmacokinetics and bioavailability of drotaverine in humans.

O O Bolaji1, C O Onyeji, A O Ogundaini, T A Olugbade, F A Ogunbona.   

Abstract

The pharmacokinetics and bioavailability of drotaverine was studied in 10 healthy volunteers after administration of single 80 mg oral and intravenous doses of the HCl salt of the drug, in a crossover fashion. Plasma and urine samples were analyzed for the unchanged drug by HPLC. The pharmacokinetic parameters, such as elimination half-life, plasma clearance, renal clearance and apparent volume of distribution, were not influenced by the route of drug administration. The drug was mainly eliminated by non-renal routes since renal clearance accounted for only 0.31 +/- 0.13% of the total plasma clearance. The absolute bioavailability was variable and ranged from 24.5-91% with a mean of 58.2 +/- 18.2% (mean +/- SD). It is suggested that the high variation in the bioavailability of drotaverine HCl after oral administration may result in significant interindividual differences in therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980918     DOI: 10.1007/BF03189716

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Variable bioavailability of papaverine.

Authors:  G Berg; K A Jönsson; M Hammar; B Norlander
Journal:  Pharmacol Toxicol       Date:  1988-05

2.  The intestinal absorption and excretion of 14C drotaverin in rats.

Authors:  G Simon; Z Vargay; M Winter; T Szüts
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

3.  Modified high-performance liquid chromatographic method for analysis of drotaverine in human plasma.

Authors:  J K Lalla; M U Shah; M B Jain; A H Sharma
Journal:  J Pharm Biomed Anal       Date:  1993 Apr-May       Impact factor: 3.935

4.  A new method for high-performance liquid chromatographic determination of drotaverine in plasma.

Authors:  J Mezei; S Küttel; P Szentmiklósi; S Marton; I Rácz
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

5.  Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms.

Authors:  E R Garrett; H Roseboom; J R Green; W Schuermann
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-05

6.  Qualitative and quantitative determination of drotaverine metabolites in rat bile.

Authors:  Z Vargay; G Simon; M Winter; T Szüts
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

7.  The influence of dosage form on papaverine bioavailability.

Authors:  M C Meyer; R Gollamudi; A B Straughn
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

8.  Absorption, distribution and elimination of drotaverine.

Authors:  K Magyar; M Lengyel; J Knoll
Journal:  Acta Physiol Acad Sci Hung       Date:  1978

9.  The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate.

Authors:  Z Vargay; T Deutsch; I Szatmári; T Szüts; P Várkonyi; S Kerpel-Fronius; S Eckhardt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

10.  High-performance liquid chromatographic method for the determination of drotaverine in human plasma and urine.

Authors:  O O Bolaji; C O Onyeji; F O Ogungbamila; F A Ogunbona; E O Ogunlana
Journal:  J Chromatogr       Date:  1993-12-08
  10 in total
  3 in total

Review 1.  Pain relief for outpatient hysteroscopy.

Authors:  Gaity Ahmad; Sushant Saluja; Helena O'Flynn; Alessandra Sorrentino; Daniel Leach; Andrew Watson
Journal:  Cochrane Database Syst Rev       Date:  2017-10-05

2.  Intramuscular Administration of Drotaverine Hydrochloride Decreases Both Incidence of Urinary Retention and Time to Micturition in Orthopedic Patients under Spinal Anesthesia: A Single Blinded Randomized Study.

Authors:  Dariusz Tomaszewski; Mariusz Bałkota
Journal:  Biomed Res Int       Date:  2015-06-21       Impact factor: 3.411

3.  The Influence of Oral Drotaverine Administration on Materno-Fetal Circulation during the Second and Third Trimester of Pregnancy.

Authors:  Paweł Rzymski; Katarzyna Maria Tomczyk; Maciej Wilczak
Journal:  Medicina (Kaunas)       Date:  2022-02-03       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.